Terms: = Endocrine gland cancer AND SLC34A2, ENSG00000157765, O95436, NPTIIb, NAPI-IIb, NAPI-3B, FLJ90534, 10568
14 results:
1. Distinct molecular subtypes of papillary thyroid carcinoma and gene signature with diagnostic capability.
Hong S; Xie Y; Cheng Z; Li J; He W; Guo Z; Zhang Q; Peng S; He M; Yu S; Xu L; Liu R; Xu T; Zhang Y; Li Y; Wang J; Lv W; Yu J; Xiao H
Oncogene; 2022 Nov; 41(47):5121-5132. PubMed ID: 36253446
[TBL] [Abstract] [Full Text] [Related]
2. Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.
Bondeson DP; Paolella BR; Asfaw A; Rothberg MV; Skipper TA; Langan C; Mesa G; Gonzalez A; Surface LE; Ito K; Kazachkova M; Colgan WN; Warren A; Dempster JM; Krill-Burger JM; Ericsson M; Tang AA; Fung I; Chambers ES; Abdusamad M; Dumont N; Doench JG; Piccioni F; Root DE; Boehm J; Hahn WC; Mannstadt M; McFarland JM; Vazquez F; Golub TR
Nat Cancer; 2022 Jun; 3(6):681-695. PubMed ID: 35437317
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of the Prognostic Value of Solute Carrier Family 34 Member 2 "slc34a2" in Papillary Thyroid Carcinoma: An Immunohistochemical Study.
Hakim SA; Abd El Atti RM; Faheim RM; Abou Gabal HH
Anal Cell Pathol (Amst); 2021; 2021():3198555. PubMed ID: 34336552
[TBL] [Abstract] [Full Text] [Related]
4. Whole-exome sequencing of non-BRCA1/BRCA2 mutation carrier cases at high-risk for hereditary breast/ovarian cancer.
Felicio PS; Grasel RS; Campacci N; de Paula AE; Galvão HCR; Torrezan GT; Sabato CS; Fernandes GC; Souza CP; Michelli RD; Andrade CE; Barros BDF; Matsushita MM; Revil T; Ragoussis J; Couch FJ; Hart SN; Reis RM; Melendez ME; Tonin PN; Carraro DM; Palmero EI
Hum Mutat; 2021 Mar; 42(3):290-299. PubMed ID: 33326660
[TBL] [Abstract] [Full Text] [Related]
5. Identification of potential novel biomarkers to differentiate malignant thyroid nodules with cytological indeterminate.
Wu D; Hu S; Hou Y; He Y; Liu S
BMC Cancer; 2020 Mar; 20(1):199. PubMed ID: 32164602
[TBL] [Abstract] [Full Text] [Related]
6. slc34a2 simultaneously promotes papillary thyroid carcinoma growth and invasion through distinct mechanisms.
He J; Zhou M; Li X; Gu S; Cao Y; Xing T; Chen W; Chu C; Gu F; Zhou J; Jin Y; Ma J; Ma D; Zou Q
Oncogene; 2020 Mar; 39(13):2658-2675. PubMed ID: 32005974
[TBL] [Abstract] [Full Text] [Related]
7. Immunohistochemical evaluation of epithelial ovarian carcinomas identifies three different expression patterns of the MX35 antigen, NaPi2b.
Levan K; Mehryar M; Mateoiu C; Albertsson P; Bäck T; Sundfeldt K
BMC Cancer; 2017 May; 17(1):303. PubMed ID: 28464843
[TBL] [Abstract] [Full Text] [Related]
8. Preclinical Development of an Anti-NaPi2b (slc34a2) Antibody-Drug Conjugate as a Therapeutic for Non-Small Cell Lung and Ovarian cancers.
Lin K; Rubinfeld B; Zhang C; Firestein R; Harstad E; Roth L; Tsai SP; Schutten M; Xu K; Hristopoulos M; Polakis P
Clin Cancer Res; 2015 Nov; 21(22):5139-50. PubMed ID: 26156394
[TBL] [Abstract] [Full Text] [Related]
9. Quantitative analysis of slc34a2 expression in different types of ovarian tumors.
Shyian M; Gryshkova V; Kostianets O; Gorshkov V; Gogolev Y; Goncharuk I; Nespryadko S; Vorobjova L; Filonenko V; Kiyamova R
Exp Oncol; 2011 Jun; 33(2):94-8. PubMed ID: 21716206
[TBL] [Abstract] [Full Text] [Related]
10. Microarray analysis of papillary thyroid cancers in Korean.
Kim HS; Kim DH; Kim JY; Jeoung NH; Lee IK; Bong JG; Jung ED
Korean J Intern Med; 2010 Dec; 25(4):399-407. PubMed ID: 21179278
[TBL] [Abstract] [Full Text] [Related]
11. Monoclonal antibody MX35 detects the membrane transporter NaPi2b (slc34a2) in human carcinomas.
Yin BW; Kiyamova R; Chua R; Caballero OL; Gout I; Gryshkova V; Bhaskaran N; Souchelnytskyi S; Hellman U; Filonenko V; Jungbluth AA; Odunsi K; Lloyd KO; Old LJ; Ritter G
Cancer Immun; 2008 Feb; 8():3. PubMed ID: 18251464
[TBL] [Abstract] [Full Text] [Related]
12. [Expression of selected genes involved in transport of ions in papillary thyroid carcinoma].
Gałeza-Kulik M; Zebracka J; Szpak-Ulczok S; Czarniecka AK; Kukulska A; Gubała E; Stojcev Z; Wiench M
Endokrynol Pol; 2006; 57 Suppl A():26-31. PubMed ID: 17091453
[TBL] [Abstract] [Full Text] [Related]
13. Gene expression profile of papillary thyroid cancer: sources of variability and diagnostic implications.
Jarzab B; Wiench M; Fujarewicz K; Simek K; Jarzab M; Oczko-Wojciechowska M; Wloch J; Czarniecka A; Chmielik E; Lange D; Pawlaczek A; Szpak S; Gubala E; Swierniak A
Cancer Res; 2005 Feb; 65(4):1587-97. PubMed ID: 15735049
[TBL] [Abstract] [Full Text] [Related]
14. Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression.
Rangel LB; Sherman-Baust CA; Wernyj RP; Schwartz DR; Cho KR; Morin PJ
Oncogene; 2003 Oct; 22(46):7225-32. PubMed ID: 14562052
[TBL] [Abstract] [Full Text] [Related]
